Home Ricerca Sedi Chi siamo Organigramma Personale Contatti Didattica Login Documenti EN
Progetti in evidenza
INCIPIT
(Link esterno)

ISTAPCA
(1138 visite)

Fondo Europeo Pesca
(566 visite)

Euro-BioImaging
(Link esterno)

Fondazione Veronesi
(Link esterno)

LightDyNAmics
(1013 visite)

 INMiND
(1138 visite)

Instruct-IT
(Link esterno)

 PRIN
(1278 visite)

 eHealthNet
(1044 visite)

Ponrec
(991 visite)

MFAG Grant
(1074 visite)

MERIT
(Link esterno)


Collegamenti



Anti-allergic properties of a new all-D synthetic immunoglobulin-binding peptide (79 visite)

Rossi M, Ruvo M, Marasco D, Colombo M, Cassani G, Verdoliva A

Mol Immunol Molecular Immunology (ISSN: 0161-5890), 2008 Jan; 45(1): 226-234.

Tipo di articolo: Journal Article,

Impact factor: 3.555

Impact factor a 5 anni: 3.583


Parole chiave: Active Cutaneous Anaphylaxis, Allergic Disorders, Passive Cutaneous Anaphylaxis, Antiallergic Agent, Beta N Acetylhexosaminidase, Binding Protein, Immunoglobulin E, Ketotifen, Tg 19320, Tg19318, Unclassified Drug, Animal Cell, Animal Experiment, Animal Model, Article, Atopy, Controlled Study, Drug Dose Increase, Enzyme Linked Immunosorbent Assay, Female, Mast Cell Degranulation, Mouse, Nonhuman, Passive Skin Anaphylaxis, Priority Journal, Protein Analysis, Protein Binding, Protein Determination, Protein Variant, Surface Plasmon Resonance, 4-Dinitrophenol, Anti-Allergic Agents, Biotinylation, Peptides, Protein Conformation, Rattus,

Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-34548305099&partnerID=40&md5=bbbcbbec674f0b3d7ccd524ecba53032

Using a combinatorial chemistry approach, we identified a tetrameric tripeptide, denoted Protein A Mimetic (PAM) or TG19318, able to bind to immunoglobulins of different classes and species. The inverso variant, with the tripeptide in the all-D configuration (D-PAM or TG19320) is described as retaining binding properties to Ig. This peptide has now been assayed as a binder for E class immunoglobulins, in linear and competitive ELISA experiments. dot-blot and surface plasmon resonance (SPR) analyses. We show that D-PAM binds IgE with high specificity and selectivity. the interaction being sufficient to inhibit anaphylactic release of beta-hexosaminidase from RBL 2H3 cells, with an IC50 value of 10 mu g/mL. Intradermal administration of D-PAM suppresses PCA in the rat, with an IC50 of 1.25 mu g/kg dose of peptide, while its intraperitoneal injection inhibits mouse PCA with an IC50 of about 7 mg/kg and an efficacy comparable to that of ketotifen. Similarly, D-PAM inhibits ACA in the mouse, with 50% suppression at 10 mg/kg. The results presented here show that the peptide is active on the studied models, with effective doses below toxicity level, hence the molecule is a promising candidate for development of a new class of anti-allergic drugs. (C) 2007 Elsevier Ltd. All rights reserved.
*** IBB - CNR ***

Tecnogen S.p.A., Localita La Fagianeria, 81015 Piana di Monte Verna, CE, Italy

Tecnogen S. p. A., Localita La Fagianeria, 81015 Piana di Monte Verna, CE, Italy
Adkinson, N.F., Eggleston, P.A., Eney, D., Goldstain, E.O., Schuberth, K.C., Bacon, J.R., Hamilton, R.G., Wheeler, B., A controlled trial of immunotherapy for asthma in allergic children (1997) N. Engl. J. Med., 336, pp. 324-33

Alter, B.P., Gaston, T., Lipton, J.M., Lack of effect of corticosteroids in W/Wv and S1/S1d mice: these strains are not a model for steroid-responsive Diamond-Blackfan anemia (1993) Eur. J. Haematol., 50, pp. 275-278

Barnes, P.J., Pedersen, S., Busse, W.W., Efficacy and safety of inhaled corticosteroids: an update (1998) Am. J. Respir. Crit. Care Med., 157, pp. S1-S53

Barnes, P.J., Therapeutic strategies for allergic diseases (1999) Nature, 402 (SUPPL), pp. B31-B38

Baylink, D.J., Glucocorticoid-induced osteoporosis (1983) N. Engl. J. Med., 309, pp. 306-308

Bousquet, J., Cabrera, P., Berkman, N., Buhl, R., Holgate, S., Wenzel, S., Fox, H., Della Cioppa, G., The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma (2005) Allergy, 60, pp. 302-308

Buku, A., Condie, B.A., Price, J.A., Mezei, M., [Ala12]MCD peptide: a lead peptide to inhibitors of immunoglobulin E binding to mast cell receptors (2005) J. Pept. Res., 66, pp. 132-137

Fassina, G., Verdoliva, A., Odierna, M.R., Ruvo, M., Cassani, G., Protein A mimetic peptide ligand for affinity purification of antibodies (1996) J. Mol. Recognit., 9, pp. 564-569

Hoffmann, A., Jamin, A., Foetisch, K., May, S., Aulepp, H., Haustein, D., Vieths, S., Determination of the allergenic activity of birch pollen and apple prick test solutions by measurement of β-hexosaminidase release from RBL 2H3 cells. Comparison with classical methods in allergen standardization (1999) Allergy, 54, pp. 446-454

Inagaki, N., Goro, S., Nagai, H., Koda, A., Pharmacological characterization of mouse ear PCA (1985) Int. Arch. Allergy Appl. Immunol., 78, pp. 113-117

Inagaki, N., Miura, T., Nagai, H., Koda, A., Active cutaneous anaphylaxis (ACA) in the mouse ear (1992) Jpn. J. Pharmacol., 59, pp. 201-208

Inagaki, N., Nagai, H., Drugs for the treatment of allergic diseases (2001) Jpn. J. Pharmacol., 86, pp. 275-280

Joly, F., Bessou, G., Benveniste, J., Ninio, E., Ketotifen inhibits paf-acether biosynthesis and beta-hexosaminidase release in mouse mast cells stimulated with antigen (1987) Eur. J. Pharma., 144, pp. 133-139

Kinet, J.P., Blank, U., Brini, A., Jouvin, M.H., Kuster, H., Mejan, O., Ra, C., The high-affinity receptor for immunoglobulin E: a target for therapy of allergic diseases (1991) Int. Arch. Allergy Appl. Immunol., 94, pp. 51-55

Lee, E., Choi, E.J., Cheong, H., Kim, Y.-R., Ryu, S.Y., Kim, K.-M., Anti-allergic actions of the leaves of Castanea crenata and isolation of an active component responsible for the inhibition of mast cell degranulation (1999) Arch. Pharm. Res., 22, pp. 320-323

Marino, M., Ruvo, M., De Falco, S., Fassina, G., Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide (2000) Nat. Biotechnol., 18, pp. 735-739

Marino, M., Rossi, M., Ruvo, M., Fassina, G., Novel molecular targets for systemic lupus erythematosus (2002) Curr. Drug Targets, 3, pp. 223-228

Marshall, G.D., Therapeutic options in allergic disease: antihistamines as systemic antiallergic agents (2000) J. Allergy Clin. Immunol., 106, pp. 303-309

Meltzer, E.O., Grant, J.A., Impact of ceterizine on the burden of allergic rhinitis (1999) Ann. Allergy Asthma Immunol., 83, pp. 455-463

Michaelsen, T.E., Ihle, Ø., Beckstrøm, K.J., Herstad, T.K., Kolberg, J., Høiby, E.A., Aase, A., Construction and functional activities of chimeric mouse-human immunoglobulin G and immunoglobulin M antibodies against the Neisseria meningitidis PorA P1.7 and P1.16 epitopes (2003) Infect. Immun., 71, pp. 5714-5723

Nakamura, G.R., Starovasnik, A., Reynolds, M.E., Lowman, H.B., A novel family of hairpin peptides that inhibit IgE activity by binding to the high-affinity IgE receptor (2001) Biochemistry, 40, pp. 9828-9835

Nakamura, G.R., Reynolds, M.E., Chen, Y.M., Starovasnik, M.A., Lowman, H.B., Stable "zeta" peptides that act as potent antagonists of the high-affinity IgE receptor (2002) Proc. Natl. Acad. Sci. U.S.A., 99, pp. 1303-1308

Ovary, Z., Immediate reactions in the skin of experimental animals provoked by antibody-antigen interaction (1958) Prog. Allergy, 5, pp. 459-508

Palombo, G., Rossi, M., Cassani, G., Fassina, G., Affinity purification of mouse monoclonal IgE using a protein A mimetic ligand (TG19318) immobilized on solid supports (1998) J. Mol. Recognit., 11, pp. 247-249

Palombo, G., De Falco, S., Tortora, M., Cassani, G., Fassina, G., A synthetic ligand for IgA affinity purification (1998) J. Mol. Recognit., 11, pp. 243-246

Palombo, G., Verdoliva, A., Fassina, G., Affinity purification of immunoglobulin M using a novel synthetic ligand (1998) J. Chromatogr. B Biomed. Sci. Appl., 715, pp. 137-145

Piper, J.M., Ray, W.A., Daugherty, J.R., Griffin, M.R., Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs (1991) Ann. Intern. Med., 114, pp. 735-740

Presta, L.G., Lahr, S.J., Shields, R.L., Porter, J.P., Gorman, C.M., Fendly, B.M., Jardieu, P.M., Humanization of an antibody direct against IgE (1993) J. Immunol., 151, pp. 2623-2632

Rigby, L.J., Trist, H., Snider, J., Hulett, M.D., Hogarth, P.M., Monoclonal antibodies and synthetic peptides define the active site of FcepsilonRI and a potential receptor antagonist (2000) Allergy, 55, pp. 609-619

Russo, A., Russo, G., Peticca, M., Pietropaolo, C., Di Rosa, M., Iuvone, T., Inhibition of granuloma-associated angiogenesis by controlling mast cell mediator release: role of mast cell protease-5 (2005) Br. J. Pharmacol., 145, pp. 24-33

Till, S.J., Francis, J.N., Nouri-Aria, K., Durham, S.R., Mechanisms of immunotherapy (2004) J. Allergy Clin. Immunol., 113, pp. 1025-1034

van der Kleij, H.P., Kraneveld, A., van Houwelingen, A.H., Kool, M., Weitemberg, A.C., Redegeld, F.A., Nijkamp, F.P., Murine model for non-IgE-mediated asthma (2004) Inflammation, 28, pp. 115-125

Verdoliva, A., Basile, G., Fassina, G., Affinity purification of immunoglobulins from chicken egg yolk using a new synthetic ligand (2000) J. Chromatogr. B, 749, pp. 233-242

Verdoliva, A., Pannone, F., Rossi, M., Catello, S., Manfredi, V., Affinity purification of polyclonal antibodies using a new all-D synthetic peptide ligand: comparison with protein A and protein G (2002) J. Immunol. Methods, 271, pp. 77-88

Wiegand, T.W., Williams, P.B., Dreskin, S.C., Jouvin, M.H., Kinet, J.P., Tasset, D., High-affinity oligonucleotide ligands to human IgE Inhibit binding to Fcε Receptor I (1996) J. Immunol., 157, pp. 221-230

Yamanishi, R., Kondo, K., Tsuji, H., Ogawa, T., Micro-assay to Measure the allergenicity of Kunitz-type Soybean Trypsin Inhibitor toward Balb/c Mice by Using RBL-2H3 Cells (1995) Biosci. Biotech. Biochem., 59, pp. 1272-1275

Yan, H., Lamm, M.E., Björling, E., Huang, Y.T., Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model (2002) J. Virol., 76, pp. 10972-10979

Adkinson, N. F., Eggleston, P. A., Eney, D., Goldstain, E. O., Schuberth, K. C., Bacon, J. R., Hamilton, R. G., Wheeler, B., A controlled trial of immunotherapy for asthma in allergic children (1997) N. Engl. J. Med., 336, pp. 324-33

Alter, B. P., Gaston, T., Lipton, J. M., Lack of effect of corticosteroids in W/Wv and S1/S1d mice: these strains are not a model for steroid-responsive Diamond-Blackfan anemia (1993) Eur. J. Haematol., 50, pp. 275-278

Barnes, P. J., Pedersen, S., Busse, W. W., Efficacy and safety of inhaled corticosteroids: an update (1998) Am. J. Respir. Crit. Care Med., 157, pp. S1-S53

Barnes, P. J., Therapeutic strategies for allergic diseases (1999) Nature, 402 (SUPPL), pp. B31-B38

Baylink, D. J., Glucocorticoid-induced osteoporosis (1983) N. Engl. J. Med., 309, pp. 306-308

Kinet, J. P., Blank, U., Brini, A., Jouvin, M. H., Kuster, H., Mejan, O., Ra, C., The high-affinity receptor for immunoglobulin E: a target for therapy of allergic diseases (1991) Int. Arch. Allergy Appl. Immunol., 94, pp. 51-55

Lee, E., Choi, E. J., Cheong, H., Kim, Y. -R., Ryu, S. Y., Kim, K. -M., Anti-allergic actions of the leaves of Castanea crenata and isolation of an active component responsible for the inhibition of mast cell degranulation (1999) Arch. Pharm. Res., 22, pp. 320-323

Marshall, G. D., Therapeutic options in allergic disease: antihistamines as systemic antiallergic agents (2000) J. Allergy Clin. Immunol., 106, pp. 303-309

Meltzer, E. O., Grant, J. A., Impact of ceterizine on the burden of allergic rhinitis (1999) Ann. Allergy Asthma Immunol., 83, pp. 455-463

Michaelsen, T. E., Ihle, ., Beckstr m, K. J., Herstad, T. K., Kolberg, J., H iby, E. A., Aase, A., Construction and functional activities of chimeric mouse-human immunoglobulin G and immunoglobulin M antibodies against the Neisseria meningitidis PorA P1. 7 and P1. 16 epitopes (2003) Infect. Immun., 71, pp. 5714-5723

Nakamura, G. R., Starovasnik, A., Reynolds, M. E., Lowman, H. B., A novel family of hairpin peptides that inhibit IgE activity by binding to the high-affinity IgE receptor (2001) Biochemistry, 40, pp. 9828-9835

Nakamura, G. R., Reynolds, M. E., Chen, Y. M., Starovasnik, M. A., Lowman, H. B., Stable "zeta" peptides that act as potent antagonists of the high-affinity IgE receptor (2002) Proc. Natl. Acad. Sci. U. S. A., 99, pp. 1303-1308

Piper, J. M., Ray, W. A., Daugherty, J. R., Griffin, M. R., Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs (1991) Ann. Intern. Med., 114, pp. 735-740

Presta, L. G., Lahr, S. J., Shields, R. L., Porter, J. P., Gorman, C. M., Fendly, B. M., Jardieu, P. M., Humanization of an antibody direct against IgE (1993) J. Immunol., 151, pp. 2623-2632

Rigby, L. J., Trist, H., Snider, J., Hulett, M. D., Hogarth, P. M., Monoclonal antibodies and synthetic peptides define the active site of FcepsilonRI and a potential receptor antagonist (2000) Allergy, 55, pp. 609-619

Till, S. J., Francis, J. N., Nouri-Aria, K., Durham, S. R., Mechanisms of immunotherapy (2004) J. Allergy Clin. Immunol., 113, pp. 1025-1034

van der Kleij, H. P., Kraneveld, A., van Houwelingen, A. H., Kool, M., Weitemberg, A. C., Redegeld, F. A., Nijkamp, F. P., Murine model for non-IgE-mediated asthma (2004) Inflammation, 28, pp. 115-125

Wiegand, T. W., Williams, P. B., Dreskin, S. C., Jouvin, M. H., Kinet, J. P., Tasset, D., High-affinity oligonucleotide ligands to human IgE Inhibit binding to Fc Receptor I (1996) J. Immunol., 157, pp. 221-230

Yan, H., Lamm, M. E., Bj rling, E., Huang, Y. T., Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model (2002) J. Virol., 76, pp. 10972-10979

Nessun risultato.
Nessun risultato.

Contiene: [X]      Estesa  
Autori: [X]
Tipo di lavoro: [X]
Data iniziale: Data finale: [X]
Sede: Affiliazione IBB
    
[Pulisci modulo]


Nessun risultato.







    Esporta in BibTeX    Esporta in EndNote

Ultima modifica di Marco Comerci in data Wednesday 26 March 2014, 9:29:57
79 visite. Ultima visita in data Monday 22 October 2018, 15:43:34

Webmaster and developer: Marco Comerci
Per problemi e suggerimenti: adminibb.cnr.it
Ultimo aggiornamento: Monday 22 October 2018, 11:52:29